TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

THIS DATA HAS BEEN REPLACED BY DIFFERENT FEATURE SERVICESTHE LAST DATE OF ENTRY WAS 8/23/2020THE DATA REPLACING THIS DATA CAN BE FOUND:SAMHD Daily Surveillance Data PublicSAMHD COVID-19 Weekly Data PublicCOVID19 Weekly Lab Testing Public------------------------------------------------------------------------------------------------------------------------------------------------------This data set contains data used to produce the public CoVID-19 Surveillance Dashboard and describes a variety of indicators of the CoVID-19 situation in the City of San Antonio and Bexar County. Each field is updated daily since the first date the data element appeared live in the Dashboard. The Surveillance Dashboard is live and available here.This data reflects information provided by the City of San Antonio Metro Health Department, and is released daily at 7PM on the City of San Antonio CoVID-19 website.

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTONWeekly COVID-19 lab testing of San Antonio residents. Provided by San Antonio Metropolitan Health District.This data reflects information provided by the City of San Antonio Metro Health Department. Table is updated every Monday as of data closed out as of the previous Friday/Weekend. Tests are both molecular (PCR/NAAT) and antigen (FIA) tests, and represent tests on those in Bexar County only.

The City of San Antonio's Open Data page for CoVID-19 surveillance data.

{{description}}

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods: This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity. Results: 1,383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32–1.67]); Black patients (aOR 1.74; 95 CI 1.24–2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70–6.79) and Other (aOR 2.97; 95 CI 1.71–5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83–12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63–3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20–2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66–3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89–22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort were 9% and 37%, respectively; however, it varied according to the BC disease status. Conclusions: Using one of the largest registries on cancer and COVID-19, we identified patient- and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to Non-Hispanic White patients.

Background: The burden of the COVID-19 pandemic in Peru has led to people seeking alternative treatments as preventives and treatment options such as medicinal plants. This study aimed to assess factors associated with the use of medicinal plants as preventive or treatment of respiratory symptom related to COVID-19 during the pandemic in Cusco, Peru.

Method: A web-based cross-sectional study was conducted on general public (20- to 70-year-old) from August 31 to September 20, 2020. Data were collected using a structured questionnaire via Google Forms, it consisted of an 11-item questionnaire that was developed and validated by expert judgment using Aiken's V (Aiken's V > 0.9). Both descriptive statistics and bivariate followed by multivariable logistic regression analyses were conducted to assess factors associated with the use of medicinal plants for COVID-19 prevention and respiratory symptom treatment during the pandemic. Prevalence ratios (PR) with 95% Confidence Interval (CI), and a P-value of 0.05 was used to determine statistical significance.

Results: A total of 1,747 respondents participated in the study, 80.2% reported that they used medicinal plants as preventives, while 71% reported that they used them to treat respiratory symptoms. At least, 24% of respondents used medicinal plants when presenting with two or more respiratory symptoms, while at least 11% used plants for malaise. For treatment or prevention, the multivariate analysis showed that most respondents used eucalyptus (p ​​< 0.001 for both), ginger (p​​ < 0.022 for both), spiked pepper (p < 0.003 for both), garlic (p = 0.023 for prevention), and chamomile (p = 0.011 for treatment). The respondents with COVID-19 (p < 0.001), at older ages (p = 0.046), and with a family member or friend who had COVID-19 (p < 0.001) used more plants for prevention. However, the respondents with technical or higher education used less plants for treatment (p < 0.001).

Conclusion: There was a significant use of medicinal plants for both prevention and treatment, which was associated with several population characteristics and whether respondents had COVID-19.

Methods We conducted an online cross-sectional multicenter survey, which was initially evaluated by 10 expert judges using Aiken's V (40). After including the experts’ observations, a pilot study was performed (from August 16 to 4) with 336 respondents in in five districts of Cusco, Peru. The pilot data was used to calculate the minimal sample size necessary for the actual study. It was determined that a minimum sample size of 1,530 was necessary to achieve a minimum percentage difference of 2.5% (49.0% versus 51.5%), a statistical power of 80%, and a confidence level of 95%. The sample size was calculated using power analysis.

The actual survey consisted of an online questionnaire that was sent via WhatsApp, Messenger, and Facebook. The shared questionnaire was made anonymous ensuring data confidentiality and reliability. The survey was performed from August 31 to September 20, 2020 after approximately 9 months of lockdown and social distancing measures in Peru due to the COVID-19 outbreak. At the beginning of the survey (August 31) the number of COVID-19 confirmed cases was 652,037 and 28,944 deaths, while at the end of the survey (September 20) the confirmed cases increased to 772,896 and the deaths increased to 31,474. We surveyed general public who were adults of both genders aged 20 to 70 years in five districts of Cusco, Peru with high-risk COVID-19 transmission according to the Epidemiological Alert AE-017-2020. The five districts were Cusco, San Jerónimo, San Sebastián, Santiago, and Wanchaq. Participants were recruited by the research team of the Universidad Nacional de San Antonio Abad del Cusco.

Context

Multisystem inflammatory syndrome in children (MIS-C), also known as pediatric inflammatory multisystem syndrome, is a new dangerous childhood disease that is temporally associated with coronavirus disease 2019 (COVID-19). We aimed to describe the typical presentation and outcomes of children diagnosed with this hyperinflammatory condition.

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30271-6/fulltext#seccesectitle0001

Content

A systematic review to communicate the clinical signs and symptoms, laboratory findings, imaging results, and outcomes of individuals with MIS-C.

Acknowledgements

Authors: Mubbasheer Ahmeda;; , Shailesh Advanib;; Axel Moreira;; , Sarah Zoretic;; , John Martinez;; Kevin Chorath;; , Sebastian Acosta;; , Rija Naqvi;; Finn Burmeister-Morton;; Fiona Burmeister;; Aina Tarriela;; , Matthew Petershack;; , Mary Evans;; , Ansel Hoang;; Karthik Rajasekaran;; , Sunil Ahuja;; Alvaro Moreira

Department of Pediatrics, Texas Children’s Hospital, Houston, TX, USA;; Department of Oncology, Georgetown University, Washington, DC, USA;; Social Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, USA;; Department of Pediatrics, University of Texas Health Science Center San Antonio, San Antonio, TX 78229-3900, USA;; Department of Otorhinolaryngology, The University of Pennsylvania, Philadelphia, PA, USA.

Photo by L N on Unsplash

Inspiration

Covid-19 Pandemic.

The City of San Antonio's Open Data page for CoVID-19 vaccination data.

TO DOWNLOAD THE DATASET, CLICK ON THE "Download" BUTTON

Demographics, clinical features and underlined health conditions of the cohort.

DO NOT DELETE OR MODIFY THIS ITEM. This item is managed by the ArcGIS Hub application. To make changes to this site, please visit https://hub.arcgis.com/admin/

According to Cognitive Market Research, the global Emerging Cancer Vaccines market size is USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of 12.50% from 2024 to 2031.

North America held the major market of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.7% from 2024 to 2031.
Europe accounted for a share of over 30% of the global market size of USD XX million.
Asia Pacific held the market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.5% from 2024 to 2031.
Latin America market of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.9% from 2024 to 2031.
Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.2% from 2024 to 2031.
The Genetic vaccines held the highest Emerging Cancer Vaccines market revenue share in 2024

Market Dynamics of Emerging Cancer Vaccines Market

Key Drivers for Emerging Cancer Vaccines Market

Increasing Prevalence of Cancer to Propel the Market Revenue Growth

One of the major factor that propel the emerging cancer market is rising prevalence of cancer across the globe as the traditional therapy such as chemotherapy and radiation therapy often have a significant side-effets. This side effects turn medical personnel for the R&D of cancer vaccines, which anticipated to drive the penetration of market revenue growth. For instance, according to the estimates by American Cancer Society, around 20 million cancer cases were newly diagnosed and 9.7 million people died from the cancer globally in 2022. This number of cancer cases is projected to grow 35 million by 2050. Thus, the aforementioned stats support the market growth.

Rising Clinical Trials to Boost Market Growth

The growing clinical trials are expected to propel the market growth during the forecast period. For instance, in December 2023, nixa Biosciences, Inc., a biotechnology business that specializes in cancer therapy and prevention, recently released updated and fresh positive data from their breast cancer vaccine's Phase 1 clinical study. The trial is being carried out with financial support from a grant from the U.S. Department of Defense in association with Cleveland Clinic.G. Thomas Budd, M.D., a staff physician at Cleveland Clinic Cancer Institute and the study's principal investigator, presented the data at the 2023 San Antonio Breast Cancer Symposium in a poster titled "Phase I Trial of alpha-lactalbumin vaccine in high-risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC.

Source: https://www.prnewswire.com/news-releases/anixa-biosciences-and-cleveland-clinic-present-positive-new-data-from-phase-1-study-of-breast-cancer-vaccine-302007568.html.

Restraint Factor for the Emerging Cancer Vaccines Market

Complexity of Cancer Immunology to Limit the Market Growth

The complexity of cancer immunology is expected to hamper the market growth during the forecast period. As cancer disease is complex and heterogeneous in nature, and immune systems response to these disease is also very complex in nature. The R&D of the effective cancer vaccines demanding a good knowledge of tumor biology, immune evasion mechanisms, and the interplay between cancer cells and the immune system. The complex nature cancer immunology is the major challenge in identifying suitable vaccine targets and optimizing vaccine design, which may impede the development of theraupeutic treatment of cancer such as vaccines.

Impact of Covid-19 on the Emerging Cancer Vaccines Market

The COVID-19 pandemic had a mix impact on the emerging cancer vaccines market. The mRNA based vaccines manufactured by the global company such as Pfizer-BioNTech and Moderna, has brought attention to the potential of mRNA technology in the production of vaccines. As the same technology is used to modified target cancer-specific antigens, which has increased demand and funding for mRNA-based cancer vaccines. Furthermore, the COVID-19 has raised awareness of the significance of immunotherapy and vaccinations in fight aginst various disease including cancer, in...